NCI Trials for Nov. 2020

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – PED-CITN-01

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers

Cancer Immunotherapy Trials Network

Morgenstern, Daniel Alexander

(416) 813-7654


Phase II – A021804

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Alliance for Clinical Trials in Oncology

Del Rivero, Jaydira

(240) 805-2888


Phase II – AMC-107

A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

AIDS Malignancy Consortium

Mitsuyasu, Ronald T.

(310) 825-6689


Phase II – EA8184

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

ECOG-ACRIN Cancer Research Group

Kumar, Nagi B.

(813) 745-6885


Phase III – EA9181

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

ECOG-ACRIN Cancer Research Group

Ofran, Yishai

+972-4-7772541


Phase III – EAA181

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

ECOG-ACRIN Cancer Research Group

Kumar, Shaji K.

(507) 284-2017


Phase III – NRG-BN009

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year

NRG Oncology

Gondi, Vinai

(630) 821-6430


Phase Other – A231901CD

Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHADES)

Alliance for Clinical Trials in Oncology

Hawley, Sarah

(734) 936-8816

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login